BRCA1 and breast carcinoma: Talazoparib is a PARP inhibitor that is approved as monotherapy for the treatment of patients with HER2-negative advanced breast cancer with a germline BRCA1/2 mutation in the United States, United Kingdom, European Union, and other countries [16, 17].